[{"orgOrder":0,"company":"Elgan Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"Inapplicable","moa":"||Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Elgan Pharma \/ European Innovation Council","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ European Innovation Council"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Elgan Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ELGN-2112","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elgan Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ELGN-2112","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elgan Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ Inapplicable"}]